YAP1 and breast carcinoma: Pharmacologic inhibitors such as verteporfin, which disrupt the YAP–TEAD interaction, have shown efficacy across multiple breast cancer subtypes [40], while upstream modulators like RNF187 have been proposed as potential targets in triple-negative disease [41].